Perceptive Advisors LLC lifted its holdings in shares of La Jolla Pharmaceutical (NASDAQ:LJPC) by 57.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,388,611 shares of the biopharmaceutical company’s stock after acquiring an additional 1,231,600 shares during the period. La Jolla Pharmaceutical accounts for approximately 3.6% of Perceptive Advisors LLC’s investment portfolio, making the stock its 6th biggest holding. Perceptive Advisors LLC owned approximately 15.30% of La Jolla Pharmaceutical worth $109,046,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also modified their holdings of LJPC. Wells Fargo & Company MN raised its position in shares of La Jolla Pharmaceutical by 23.0% during the 2nd quarter. Wells Fargo & Company MN now owns 16,937 shares of the biopharmaceutical company’s stock worth $504,000 after acquiring an additional 3,167 shares in the last quarter. New York State Common Retirement Fund raised its position in shares of La Jolla Pharmaceutical by 21.2% during the 2nd quarter. New York State Common Retirement Fund now owns 18,300 shares of the biopharmaceutical company’s stock worth $545,000 after acquiring an additional 3,199 shares in the last quarter. Vanguard Group Inc. raised its position in shares of La Jolla Pharmaceutical by 23.3% during the 2nd quarter. Vanguard Group Inc. now owns 816,779 shares of the biopharmaceutical company’s stock worth $24,316,000 after acquiring an additional 154,494 shares in the last quarter. Voya Investment Management LLC acquired a new stake in shares of La Jolla Pharmaceutical during the 2nd quarter worth about $243,000. Finally, The Manufacturers Life Insurance Company raised its position in shares of La Jolla Pharmaceutical by 19.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,397 shares of the biopharmaceutical company’s stock worth $399,000 after acquiring an additional 2,162 shares in the last quarter.
In related news, Director Kevin C. Tang bought 10,000 shares of the stock in a transaction on Friday, March 2nd. The shares were bought at an average cost of $30.44 per share, for a total transaction of $304,400.00. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Kevin C. Tang bought 150,000 shares of the stock in a transaction on Tuesday, February 27th. The stock was bought at an average price of $31.82 per share, for a total transaction of $4,773,000.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 338,000 shares of company stock worth $10,902,320 in the last 90 days. 25.47% of the stock is currently owned by company insiders.
La Jolla Pharmaceutical (LJPC) opened at $33.69 on Monday. The stock has a market capitalization of $746.07, a P/E ratio of -6.24 and a beta of 1.29. La Jolla Pharmaceutical has a 12 month low of $22.68 and a 12 month high of $41.36.
La Jolla Pharmaceutical (NASDAQ:LJPC) last released its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.25) by ($0.49). analysts forecast that La Jolla Pharmaceutical will post -5 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Perceptive Advisors LLC Acquires 1,231,600 Shares of La Jolla Pharmaceutical (LJPC)” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/03/12/perceptive-advisors-llc-acquires-1231600-shares-of-la-jolla-pharmaceutical-ljpc.html.
La Jolla Pharmaceutical Company Profile
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).
Want to see what other hedge funds are holding LJPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for La Jolla Pharmaceutical (NASDAQ:LJPC).
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.